Everything below concerns fatty acid oxidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
The largest amounts of estradiol are produced by the granulosa cells of the ovaries, but lesser amounts are derived from testicular and adrenal testosterone. Adrenal androgens are steroids produced by the zona reticulosa of the adrenal cortex in both sexes. The major adrenal androgens are dehydroepiandrosterone, androstenedione (which are precursors of testosterone), and dehydroepiandrosterone sulfate which is present in large amounts in the blood. Adrenal androgens contribute to the androgenic events of early puberty in females. IGF1 (insulin-like growth factor 1) rises substantially during puberty in response to rising levels of growth hormone and may be the principal mediator of the pubertal growth spurt. Leptin is a protein hormone produced by adipose tissue. Its primary target organ is the hypothalamus. The leptin level seems to provide the brain a rough indicator of adipose mass for purposes of regulation of appetite and energy metabolism. It also plays a permissive role in female puberty, which usually will not proceed until an adequate body mass has been achieved.
==== Exogenous ==== Exogenous pyrogens are external to the body and are of microbial origin. In general, these pyrogens, including bacterial cell wall products, may act on Toll-like receptors in the hypothalamus and elevate the thermoregulatory setpoint. An example of a class of exogenous pyrogens are bacterial lipopolysaccharides (LPS) present in the cell wall of gram-negative bacteria. According to one mechanism of pyrogen action, an immune system protein, lipopolysaccharide-binding protein (LBP), binds to LPS, and the LBP–LPS complex then binds to a CD14 receptor on a macrophage. The LBP-LPS binding to CD14 results in cellular synthesis and release of various endogenous cytokines, e.g., interleukin 1 (IL-1), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNFα). A further downstream event is activation of the arachidonic acid pathway.
==== Before birth ==== Mammary gland development is characterized by the unique process by which the epithelium invades the stroma. The development of the mammary gland occurs mainly after birth. During puberty, tubule formation is coupled with branching morphogenesis which establishes the basic arboreal network of ducts emanating from the nipple. Developmentally, mammary gland epithelium is constantly produced and maintained by rare epithelial cells, dubbed as mammary progenitors which are ultimately thought to be derived from tissue-resident stem cells. Embryonic mammary gland development can be divided into a series of specific stages. Initially, the formation of the milk lines that run between the fore and hind limbs bilaterally on each side of the midline occurs around embryonic day 10.5 (E10.5). The second stage occurs at E11.5 when placode formation begins along the mammary milk line. This will eventually give rise to the nipple. Lastly, the third stage occurs at E12.5 and involves the invagination of cells within the placode into the mesenchyme, leading to a mammary anlage (biology). The primitive (stem) cells are detected in the embryo and their numbers increase steadily during development.
Often in the continuation of this anaerobic exercise, the product from this metabolic mechanism builds up in what is called lactic acid fermentation. Lactate is produced more quickly than it is being removed and it serves to regenerate NAD+ cells on where it's needed. During intense exercise when oxygen is not being used, a high amount of ATP is produced and pH levels fall causing acidosis or more specifically lactic acidosis. Lactic acid build up can be treated by staying well-hydrated throughout and especially after the workout, having an efficient cool down routine and good post-workout stretching. Intense activity can cause significant and permanent damage to bodily tissues. In order to repair, vitamin E and other antioxidants are needed to protect muscle damage. Oxidation damage and muscle tissue breakdown happens during endurance running so athletes need to eat foods high in protein in order to repair these muscle tissues. It is important for female endurance runners to consume proper nutrients in their diet that will repair, fuel, and minimize fatigue and injury. To keep a female runner's body performing at its best, the ten nutrients need to be included in their diets.
E-cigarette vapor potentially contains harmful chemicals not found in tobacco smoke. E-cigarette vapor contains fewer toxic chemicals, and lower concentrations of potential toxic chemicals than cigarette smoke. The vapor is probably much less harmful to users and bystanders than cigarette smoke, although concern exists that the exhaled vapor may be inhaled by non-users, particularly indoors.
Sources: en.wikipedia.org
== Environmental impact == An unexpected negative environmental impact of chelating agents, as DTPA, is their toxicity for the activated sludges in the treatment of Kraft pulping effluents. Most of the DTPA worldwide production (several thousands of tons) is intended to avoid hydrogen peroxide decomposition by redox-active iron and manganese ions in the chlorine-free Kraft pulping processes (total chlorine free (TCF) and environmental chlorine free (ECF) processes). DTPA decreases the biological oxygen demand (BOD) of activated sludges and therefore their microbial activity.
=== Precautions === Excessive consumption of parsley should be avoided by pregnant women. Normal food quantities are safe for pregnant women, but consuming excessively large amounts may have uterotonic effects.
Acatalasia (acatalasemia, Takahara's disease) Acquired dyskeratotic leukoplakia Actinic cheilitis (actinic cheilosis) Acute necrotizing ulcerative gingivitis (acute membranous gingivitis, acute necrotizing ulcerative gingivostomatitis, fusospirillary gingivitis, fusospirillosis, fusospirochetal gingivitis, necrotizing gingivitis, phagedenic gingivitis, trench mouth, ulcerative gingivitis, Vincent gingivitis, Vincent infection, Vincent stomatitis, Vincent's disease) Allergic contact cheilitis Angina bullosa haemorrhagica Angular cheilitis (perlèche) Behçet's disease (Behçet's syndrome, oculo-oral-genital syndrome) Black hairy tongue (hairy tongue, lingua villosa nigra) Caviar tongue Cheilitis exfoliativa Cheilitis glandularis Cheilitis granulomatosa (granulomatous cheilitis, orofacial granulomatosis) Cutaneous sinus of dental origin (dental sinus) Cyclic neutropenia Desquamative gingivitis Drug-induced ulcer of the lip Epidermization of the lip Epulis Epulis fissuratum (granuloma fissuratum) Eruptive lingual papillitis Erythroplakia (erythroplasia) Fissured tongue (furrowed tongue, lingua plicata, plicated tongue, scrotal tongue) Geographic tongue (benign migratory glossitis, benign migratory stomatitis, glossitis areata exfoliativa, glossitis areata migrans, lingua geographica, stomatitis areata migrans, transitory benign plaques of the tongue) Gingival fibroma Gingival hypertrophy Hairy leukoplakia (oral hairy leukoplakia) Intraoral dental sinus Linea alba Leukoplakia Leukoplakia with tylosis and esophageal carcinoma Major aphthous ulcer (periadenitis mucosa necrotica recurrens) Median rhomboid glossitis (central papillary atrophy) Melanocytic oral lesion Melkersson–Rosenthal syndrome Morsicatio buccarum (chronic cheek biting, chronic cheek chewing) Mucosal squamous cell carcinoma Mucous cyst of the oral mucosa (mucocele) Nagayama's spots Oral Crohn's disease Oral florid papillomatosis Oral melanosis Osseous choristoma of the tongue Peripheral ameloblastoma Plasma cell cheilitis (plasma cell gingivitis, plasma cell orificial mucositi) Plasmoacanthoma Proliferative verrucous leukoplakia Pyogenic granuloma (eruptive hemangioma, granulation tissue-type hemangioma, granuloma gravidarum, lobular capillary hemangioma, pregnancy tumor, tumor of pregnancy) Pyostomatitis vegetans Recurrent aphthous stomatitis (aphthosis, canker sores, recurrent oral aphthae) Recurrent intraoral herpes simplex infection Smooth tongue (atrophic glossitis, bald tongue, hunter glossitis, moeller) Stomatitis nicotina (nicotine stomatitis, smoker's keratosis, smoker's patches) Torus palatinus Trumpeter's wart Vestibular papillomatosis White sponge nevus (white sponge nevus of Cannon)
In June 2023, The U.S. Food and Drug Administration (FDA) authorized for marketing Eroxon, an over-the-counter non-medicated hydro-alcoholic gel indicated for treatment of erectile dysfunction. In the clinical trial, erection was achieved by most men within ten minutes after applying the gel. The gel is manufactured by Futura Medical, a British medical company. The gel is regulated as a medical device and not as a drug, because its mode of action is a physical one and it doesn't have an active pharmaceutical ingredient. Eroxon is the first topical ED treatment sold over the counter in the United States. The gel had been on sale in Europe under a CE mark since 2023, and it reached American shops in October 2024. As of 2026, the gel is sold in the United States, United Kingdom, Europe, and several countries in Latin America and the Middle East.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.